

Leadership

Time/Location

Thursday, May 1, 2025 10:30 a.m. - 12:30 p.m. Room: Bayview Room (Bay Level)

Agenda

NCORP Grant Renewal Updates – Dawn Hershman, Scott Ramsey, Veena Shankaran

Patient Advocate Updates – Barbara Segarra-Vazquez

Presentations

Al for Precision Oncology: Validation on Completed Clinical Trials –
Anant Madabhushi, PhD, Professor, Biomedical Engineering, Emory
University and Georgia Tech

Developing Studies

- **S2417CD**, A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance Dr. Christine Veenstra, MD, University of Michigan, Sarah Hawley, PhD, University of Michigan
- **S2424CD**, Lay Health Worker-led Intervention to Promote Goals of Care Communication Manali Patel, MD, MPH, MS, Stanford University; Ravi Parikh, MD, Emory University; Christopher Manz, MD, Dana Farber Cancer Institute
- Employment and Related Outcomes in Newly Diagnosed Patients with Metastatic Breast Cancer, Claire Sathe, MD, Columbia University Irving Medical Center
- Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, MD, MBA, Izumi Okado, PhD, University of Hawaii
- Patient, Provider, and Care Delivery Impacts of Immediate Release of Radiology Reports in Advanced Cancer Dr. Veena Shankaran, MD, University of Washington.

Active Studies

S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic

Hormone Receptor Positive HER-2 Breast Cancer," Dr. Melissa Accordino, MD, Columbia University Irving Medical Center Activated 7/16/18.

Recently Completed Accrual Studies

- **S1912CD**, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Veena Shankaran, MD. Activated 7/26/21. Closed: 12/16/24.
- <u>\$2108CD</u>, "A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Drs. J. Rueter, M. Trivedi, B. Symington, P. Tseng, D. Hershman, S. Ramsey. Activated: 8/22/22. Closed: 11/22/24.

Closed Studies

- S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.
- **S1417CD**, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

<u>\$1806</u>, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger



Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1415CD/Other Intracluster Correlation Coefficients from Cluster Randomized Trials Conducted within the NCI Community Oncology Research Program (NCORP). Snavely A, Gunn H, Lee J-W,. Pugh S, Barlow W, Culakova E, Arnold K, Kittel C, Smith S, Hanlon B, Tan A, Dockter T, Zahrieh D, Dressler E. JNCI Monographs Mar 1;2025(68):65-72. 2025. https://pubmed.ncbi.nlm.nih.gov/39989039/

Multiple Studies Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants.. Presant C, Vaidya R, Till C, Ashing K, Warren G, Hershman D, Sun V, Salgia R, Massarelli E, Mortimer J, Idos G, Pal S, Dorff T, Amini A, Erhunmwunsee L, Phillips T, Johnson A, Adesunloye B, Bedell F, Tergas A, Amanam I, Rosen S, Unger J. Cancer Jan 1;131(1):e35560, 2025.

https://pubmed.ncbi.nlm.nih.gov/39283236/

Multiple Studies When to Adjust for Multiplicity in Cancer Clinical Trials.

Unger J, Mazza G, Elsaid M, Duan F, Dressler E, Snavely A, Enserro D,

Pugh S.JNCI Monographs, Mar 1;2025(68):3-9, 2025.

https://pubmed.ncbi.nlm.nih.gov/39989044/

Multiple Studies Best practices and pragmatic approaches for PRO/QOL measures in cancer clinical trials. Bandos H, Torres-Saavedra P, Culacova E, Gunn H, Lee M, Duan F, Cecchini R, Unger J, Dueck A, Steingrimsson. JNCI Monographs, Mar 1;2025(68):14-21, 2025.

https://pubmed.ncbi.nlm.nih.gov/39989038/

Multiple Studies* Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J.. Breast Cancer Res Treat Feb;209(3):603-611, 2025. [*S0927,S1200,S1202] https://pubmed.ncbi.nlm.nih.gov/39560823/

Multiple Studies Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research.

Dressler E, Pugh S, Unger J, Gunn H, Zahrieh D, Snavely A. JNCI Monographs, Mar 1;2025(68):56-64, 2025.

https://pubmed.ncbi.nlm.nih.gov/39989035/

<u>Multiple Studies</u> Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. Gupta A, Till C, Vaidya R, Hershman DL, Unger JM. JAMA Netw Open. Mar 3;8(3):e250778, 2025.

https://pubmed.ncbi.nlm.nih.gov/40080017/

Multiple Studies Design and Analysis Considerations for Investigating Patient Subgroups of Interest Within Cancer Clinical Trials. Mazza G, Culacova E, Enserro D, Dignam J, Unger J. JNCI Monographs Mar 1;2025(68):22-29, 2025. https://pubmed.ncbi.nlm.nih.gov/39989043/

Submitted Manuscripts

None this cycle



Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>\$1703</i>	S1912CD	S2108CD	A191901	A231901CD	EAQ222CD	NHLBIMDS
Banner University Medical Center - Tucson	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	1	-	3
Bay Area Tumor Institute NCORP	-	1	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	-	-	5
Cancer Research Consortium of West Michigan NCORP	-	9	-	-	1	-	-
Cancer Research for the Ozarks NCORP	-	11	44	-	-	-	-
Cancer Research of Wisconsin & N. Michigan Consortium	14	19	61	1	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	10	2	132	-	-	-	1
Columbia University Minority Underserved NCORP	26	10	-	-	-	-	24
Columbus NCI Comm Oncology Research Program	4	-	-	-	-	-	-
CommonSpirit Health Research Institute	12	2	54	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	2
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	3	1	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	132	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	23
Georgia Cares Minority Underserved NCORP	-	12	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	3	-	31	-	-	-	-
Gulf South Minority Underserved NCORP	6	3	-	-	-	-	-
Hawaii Minority Underserved NCORP	11	14	100	-	-	4	5
Heartland Cancer Research NCORP	25	7	237	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	4	-	-	1
Kaiser Permanente NCI Comm Oncology Research Program	5	17	-	-	-	-	9
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	4
Kansas Institute of Medicine Cancer & Blood Center	-	-	-	-	-	-	2
Lahey Hospital & Medical Center	4	-	-	-	-	-	-
Loyola University Medical Center	3	-	-	7	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	6
Massachusetts Veterans Epidemiology Research & Information Cntr	-	-	-	-	-	-	35
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	5
Michigan Cancer Research Consortium NCORP	16	21	94	-	-	-	-



Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>\$1703</i>	S1912CD	S2108CD	A191901	A231901CD	EAQ222CD	NHLBIMDS
Moffitt Cancer Center	-	-	-	-	-	-	8
Montana Cancer Consortium NCORP	11	7	69	-	-	-	-
Mount Sinai Hospital	7	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-
NCORP of the Carolinas	6	2	-	-	-	-	2
Nevada Cancer Research Foundation NCORP	2	2	-	1	-	-	-
New Mexico Minority Underserved NCORP	16	28	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	18
Oregon Health & Science University	-	-	-	-	-	-	12
Pacific Cancer Research Consortium NCORP	10	30	-	-	-	-	-
Riverside Methodist Hospital	2	-	-	-	-	-	-
Salem Hospital	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	6	37	18	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	3	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	27
UC San Diego Moores Cancer Center	-	-	-	-	-	-	34
Universidad de la Republica - Facultad de Medicina	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	16
University of Kansas Cancer Center - MCA Rural MU NCORP	9	11	95	-	-	-	-
University of Rochester LAPS	4	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-
Upstate Carolina NCORP	-	10	<i>7</i> 3	-	-	-	-
Western States Cancer Research NCORP	-	2	-	1	-	1	-
Wisconsin NCI Comm Oncology Research Program	8	4	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	49	-	-	-	-	-	7
ALLIANCE	17	19	81	-	-	-	-
ECOG-ACRIN	28	31	63	-	-	-	-
NRG	20	16	-	-	-	-	-
Total	376	331	1,284	41	2	5	249





